Accelerating early phase development in the UK and Germany

Recent changes in the regulatory environment post-pandemic and the introduction of EU-CTR 536/2014 are making the UK and Germany more attractive to biotech drug developers. In this video, Parexel experts provide an update on recent early-phase regulatory timelines in the UK and Germany, resulting in trial efficiencies and accelerated approvals for biopharmaceutical companies.

Also, our thought leaders answer your questions about recent changes with the MHRA and EU-CTR process, approval timelines, and the government’s efforts to make these key regions more attractive for conducting clinical trials.

Parexel Biotech can connect every step of development with you. Our Early Phase services combine clinical pharmacology and regulatory expertise to help you move swiftly and efficiently to the proof of concept milestone. Learn more about our clinical units and integrated Early Phase expertise.

Return to Insights Center

Related Insights

Blog

Best practices for maximizing early-phase trial efficiency to accelerate regulatory timelines

Apr 4, 2024

Blog

Making cell and gene therapy more accessible in the treatment of solid tumors

Jun 4, 2024

Article

The technologies that are reshaping biotherapeutics manufacturing, an EU perspective

Jul 6, 2023

Video

How to transition existing trials under EU-CTR

Feb 1, 2023

Webinar

How to navigate China’s regulatory environment

Feb 15, 2023

Whitepaper

The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations

Mar 9, 2023

Playbook

Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success

Mar 28, 2023

Video

The science and practice of ethnobridging

May 17, 2023

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Report

New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023

Webinar

Assessing appropriate use of ECAs in clinical trials

May 28, 2023

Blog

Celebrating 40 Years of Rare Disease Progress: WODC Highlights

Jun 6, 2023

Related Insights

Blog

Best practices for maximizing early-phase trial efficiency to accelerate regulatory timelines

Apr 4, 2024

Blog

Making cell and gene therapy more accessible in the treatment of solid tumors

Jun 4, 2024

Article

The technologies that are reshaping biotherapeutics manufacturing, an EU perspective

Jul 6, 2023

Video

How to transition existing trials under EU-CTR

Feb 1, 2023

Webinar

How to navigate China’s regulatory environment

Feb 15, 2023

Whitepaper

The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations

Mar 9, 2023

Show more